Immupharma PLC Appointment of Company Secretary
December 04 2024 - 1:00AM
RNS Regulatory News
RNS Number : 4674O
Immupharma PLC
04 December 2024
3 December 2024
ImmuPharma
PLC
("ImmuPharma" or the "Company")
Appointment of Company
Secretary
ImmuPharma PLC (LSE:IMM), the
specialist drug discovery and development company, is pleased to
confirm the appointment of Ashley Clarke ACA, as Company Secretary
to the Company. The appointment is with immediate
effect.
Ashley has been closely involved
with the Company's accounts for several years via outsourced
accountants, providing her with deep familiarity with ImmuPharma's
operations. Now, as Group CFO, she is poised to leverage her
extensive knowledge to drive strategic financial growth and ensure
continued robust fiscal management. (More details on Ashley in
'Notes to Editors').
Ends
This announcement contains inside information as stipulated
under the UK version of the Market Abuse Regulation no 596/2014
which is part of English law by virtue of the European (withdrawal)
Act 2018, as amended. On publication of this announcement via
a regulatory information service, this information is considered to
be in the public domain.
For further information please
contact:
ImmuPharma PLC (www.immupharma.co.uk)
Tim McCarthy, Chief Executive
Officer
Lisa Baderoon, Head of Investor
Relations
|
+44 (0) 207 206 2650
+ 44 (0) 7721 413496
|
|
|
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
Stanford Capital Partners (Joint Broker)
Patrick Claridge, Bob
Pountney
SI
Capital (Joint Broker)
Nick Emerson
|
+44 (0) 203
368 3550
+44 (0) 20 3650 3650
+44 (0) 1483 413500
|
|
|
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases and anti-infectives.
The lead program, P140,is a first-in class "immune tolerance
restorer" for the treatment of SLE (Systemic Lupus Erythematosus)
and CIDP (Chronic Idiopathic Demyelinating Polyneuropathy) and
preclinical models suggest therapeutic activity for many other
autoimmune diseases that share the same mechanism of
action.
For additional information about
ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity
Identifier) code : 213800VZKGHXC7VUS895.
Ashley Clarke ACA
Ashley has over a decade of
experience in the financial sector, moving from a career in
auditing, where she developed expertise working with a diverse
portfolio of audit and non-audit clients across various industries.
Ashley's experience spans from supporting SMEs to managing large
international group consolidations, giving her a comprehensive
understanding of financial management across different business
scales.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
COSBSBDDDXGDGSD
Immupharma (LSE:IMM)
Historical Stock Chart
From Nov 2024 to Dec 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Dec 2023 to Dec 2024